Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients

Thomas J. Walsh, Maureen Roden, Emmanuel Roilides, Andreas Groll

Research output: Contribution to journalArticle

Abstract

Fundamental to the successful implementation of antifungal compounds in neutropenic patients is the appropriate design of comparative clinical trials investigating their safety and efficacy. The key elements of comparative clinical trial design include issues of enrolment, stratification, randomization, blinding, administration of study drugs, monitoring of drug toxicity, definitions, and key statistical elements of end points, sample size, and tools for data analysis. The initial selection of compounds and the timing of initiation of antifungal therapy in comparative clinical trials are predicated to a large degree on the in vitro and in vivo activities, plasma pharmacokinetics, profiles of safety and toxicity of the study drugs. Phase I and II studies have a critical role in designing comparative clinical trials of antifungal therapy by providing data on safety, tolerance, and plasma pharmacokinetics of the investigational agent. As new antifungal agents are developed in response to the challenge of invasive fungal infections in immunocompromised patients with cancer, thoughtfully designed and carefully implemented clinical trials will be essential in determining the future utility of these promising compounds. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)151-156
Number of pages6
JournalInternational Journal of Antimicrobial Agents
Volume16
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Clinical Trials
Drug-Related Side Effects and Adverse Reactions
Safety
Pharmacokinetics
Therapeutics
Drug Monitoring
Antifungal Agents
Immunocompromised Host
Random Allocation
Sample Size
Neoplasms

Keywords

  • Antifungal therapy
  • Cancer
  • Neutropenic patients

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Microbiology
  • Parasitology
  • Virology
  • Immunology and Allergy
  • Infectious Diseases

Cite this

Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients. / Walsh, Thomas J.; Roden, Maureen; Roilides, Emmanuel; Groll, Andreas.

In: International Journal of Antimicrobial Agents, Vol. 16, No. 2, 2000, p. 151-156.

Research output: Contribution to journalArticle

Walsh, Thomas J. ; Roden, Maureen ; Roilides, Emmanuel ; Groll, Andreas. / Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients. In: International Journal of Antimicrobial Agents. 2000 ; Vol. 16, No. 2. pp. 151-156.
@article{6e8195a329464d01a8c8de4e989c1718,
title = "Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients",
abstract = "Fundamental to the successful implementation of antifungal compounds in neutropenic patients is the appropriate design of comparative clinical trials investigating their safety and efficacy. The key elements of comparative clinical trial design include issues of enrolment, stratification, randomization, blinding, administration of study drugs, monitoring of drug toxicity, definitions, and key statistical elements of end points, sample size, and tools for data analysis. The initial selection of compounds and the timing of initiation of antifungal therapy in comparative clinical trials are predicated to a large degree on the in vitro and in vivo activities, plasma pharmacokinetics, profiles of safety and toxicity of the study drugs. Phase I and II studies have a critical role in designing comparative clinical trials of antifungal therapy by providing data on safety, tolerance, and plasma pharmacokinetics of the investigational agent. As new antifungal agents are developed in response to the challenge of invasive fungal infections in immunocompromised patients with cancer, thoughtfully designed and carefully implemented clinical trials will be essential in determining the future utility of these promising compounds. Copyright (C) 2000 Elsevier Science B.V.",
keywords = "Antifungal therapy, Cancer, Neutropenic patients",
author = "Walsh, {Thomas J.} and Maureen Roden and Emmanuel Roilides and Andreas Groll",
year = "2000",
doi = "10.1016/S0924-8579(00)00242-9",
language = "English (US)",
volume = "16",
pages = "151--156",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Concepts in design of comparative clinical trials of antifungal therapy in neutropenic patients

AU - Walsh, Thomas J.

AU - Roden, Maureen

AU - Roilides, Emmanuel

AU - Groll, Andreas

PY - 2000

Y1 - 2000

N2 - Fundamental to the successful implementation of antifungal compounds in neutropenic patients is the appropriate design of comparative clinical trials investigating their safety and efficacy. The key elements of comparative clinical trial design include issues of enrolment, stratification, randomization, blinding, administration of study drugs, monitoring of drug toxicity, definitions, and key statistical elements of end points, sample size, and tools for data analysis. The initial selection of compounds and the timing of initiation of antifungal therapy in comparative clinical trials are predicated to a large degree on the in vitro and in vivo activities, plasma pharmacokinetics, profiles of safety and toxicity of the study drugs. Phase I and II studies have a critical role in designing comparative clinical trials of antifungal therapy by providing data on safety, tolerance, and plasma pharmacokinetics of the investigational agent. As new antifungal agents are developed in response to the challenge of invasive fungal infections in immunocompromised patients with cancer, thoughtfully designed and carefully implemented clinical trials will be essential in determining the future utility of these promising compounds. Copyright (C) 2000 Elsevier Science B.V.

AB - Fundamental to the successful implementation of antifungal compounds in neutropenic patients is the appropriate design of comparative clinical trials investigating their safety and efficacy. The key elements of comparative clinical trial design include issues of enrolment, stratification, randomization, blinding, administration of study drugs, monitoring of drug toxicity, definitions, and key statistical elements of end points, sample size, and tools for data analysis. The initial selection of compounds and the timing of initiation of antifungal therapy in comparative clinical trials are predicated to a large degree on the in vitro and in vivo activities, plasma pharmacokinetics, profiles of safety and toxicity of the study drugs. Phase I and II studies have a critical role in designing comparative clinical trials of antifungal therapy by providing data on safety, tolerance, and plasma pharmacokinetics of the investigational agent. As new antifungal agents are developed in response to the challenge of invasive fungal infections in immunocompromised patients with cancer, thoughtfully designed and carefully implemented clinical trials will be essential in determining the future utility of these promising compounds. Copyright (C) 2000 Elsevier Science B.V.

KW - Antifungal therapy

KW - Cancer

KW - Neutropenic patients

UR - http://www.scopus.com/inward/record.url?scp=0033776233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033776233&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(00)00242-9

DO - 10.1016/S0924-8579(00)00242-9

M3 - Article

C2 - 11053799

AN - SCOPUS:0033776233

VL - 16

SP - 151

EP - 156

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - 2

ER -